Incyte Secures FDA Approval for PD-1 Inhibitor in First-Line Treatment of Anal Cancer
Incyte’s Zynyz Secures First-Line Approval in Anal Cancer, Marking a Milestone for PD-1 Therapy in Rare Tumor Type In a significant development for the treatment of a rare and underserved…
Teen Scientists Win Over $9M at 75th Regeneron ISEF 2025
Global Youth Scientists Shine at 75th Regeneron ISEF, Sharing Over $9 Million in Prizes In a celebration of youthful brilliance, scientific curiosity, and international collaboration, the 75th Annual Regeneron International…
EU Approves Bristol Myers’ Opdivo Regimen for Resectable High-Risk NSCLC with PD-L1 ≥1%
European Commission Grants Approval to Bristol Myers Squibb’s Perioperative Opdivo Regimen for Resectable, High-Risk NSCLC with PD-L1 Expression ≥1% Bristol Myers Squibb has announced that the European Commission (EC) has…
Merck to Present New PAH Data at ATS 2025 Conference
Merck to Present Robust Set of Pulmonary Arterial Hypertension Data at ATS 2025, Underscoring Long-Term Commitment to Innovation and Patient Outcomes Merck , known as MSD outside the United States…
Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down
Leadership Transition at Novo Nordisk: CEO Lars Fruergaard Jørgensen to Step Down Amid Market Headwinds and Strategic Realignment In a significant leadership transition, Novo Nordisk A/S announced that Lars Fruergaard…
FDA Approves Zynyz® as First-Line Treatment for Advanced Anal Cancer in the U.S.
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr), the First and Only Approved First-Line Treatment for Advanced Anal Cancer in the U.S. Incyte Corporation (Nasdaq: INCY), a global biopharmaceutical company focused…
Merck Demonstrates Resilience with Continued Growth
Merck Delivers Resilient Growth Across All Divisions in Q1 2025, Advances Strategic Expansion with SpringWorks Acquisition Merck, the global science and technology powerhouse, began 2025 on strong footing, demonstrating solid…
Regeneron Wins Antitrust Suit Against Amgen Over PCSK9 Drug Access
Regeneron Triumphs in Landmark Antitrust Case Against Amgen Over PCSK9 Inhibitor Market Practices In a major legal victory that could have lasting implications for the biotechnology and pharmaceutical industries, Regeneron…
CSL Behring Named 2025 ISPE Facility of the Year Award Winner
CSL Behring’s Broadmeadows Plasma Facility Wins Prestigious 2025 ISPE Facility of the Year Award for Pharma 4.0 Innovation CSL Behring has earned global recognition for its trailblazing approach to pharmaceutical…
Gilead and Kite to Present Key CAR T and Cancer Data at 2025 ASCO and EHA
Gilead and Kite Set to Showcase Transformative Oncology Data at 2025 ASCO and EHA Conferences, Highlighting Advances in Breast Cancer, Multiple Myeloma, and Glioblastoma Gilead Sciences,and its Kite subsidiary are…
Merck’s Phase 3 KEYNOTE-B96 Trial Meets PFS Goal in Platinum-Resistant Ovarian Cancer
Merck’s KEYTRUDA-Based Regimen Achieves Major Milestone in Phase 3 KEYNOTE-B96 Trial for Platinum-Resistant Ovarian Cancer Merck & Co., Inc. (NYSE: MRK), operating as MSD outside the United States and Canada,…
GSK to Acquire Phase III-Ready Efimosfermin for Steatotic Liver Disease
GSK Acquires Phase III-Ready Efimosfermin for $1.2 Billion in Bid to Transform Steatotic Liver Disease Treatment GSK has announced a major strategic acquisition in the field of hepatology, entering into…